It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Mitochondrial-secreted growth differentiation factor-15 (GDF-15) promotes weight loss in animals. Its effects in humans remain unclear, due to limited research and potential measurement interference from the H202D-variant. Our post-hoc analysis investigates total (irrespective of genetic variants) and H-specific GDF-15 (detected only in H202D-variant absence) in humans under acute and chronic energy deprivation, examining GDF-15 interaction with leptin (energy homeostasis regulator) and GDF-15 biologic activity modulation by the H202D-variant. Total and H-specific GDF-15 increased with acute starvation, and total GDF-15 increased with chronic energy deprivation, compared with healthy subjects and regardless of leptin repletion. Baseline GDF-15 positively correlated with triglyceride-rich particles and lipoproteins. During acute metabolic stress, GDF-15 associations with metabolites/lipids appeared to differ in subjects with the H202D-variant. Our findings suggest GDF-15 increases with energy deprivation in humans, questioning its proposed weight loss and suggesting its function as a mitokine, reflecting or mediating metabolic stress response.
GDF15 is secreted my mitochondria and promotes weight loss in animals, but its effect in humans remain unclear. Here, they authors show that in humans, GDG15 is increase in females with chronic caloric deficit, independent of leptin levels, and that it’s positively correlated with triglyceride-rich particiles.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Harvard Medical School, Department of Medicine, Beth-Israel Deaconess Medical Center, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
2 UCLA, Department of Medicine, David Geffen School of Medicine, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)
3 Labcorp, Morrisville, USA (GRID:grid.419316.8) (ISNI:0000 0004 0550 1859)
4 Harvard Medical School, Department of Medicine, Beth-Israel Deaconess Medical Center, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Boston VA Healthcare System, Department of Medicine, Boston, USA (GRID:grid.410370.1) (ISNI:0000 0004 4657 1992)